DNA Ginkgo Bioworks Holdings, Inc.

NYSE ginkgobioworks.com


$ 13.14 $ 0.98 (8.16 %)    

Friday, 31-Oct-2025 18:34:20 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 12.99
$ 12.13
$ 12.84 x 45
$ 13.17 x 4
$ 12.10 - $ 13.18
$ 5.00 - $ 17.58
1,310,916
na
769M
$ 2.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-06-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-24-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ginkgo-bioworks-extends-its-multi-year-partnership-with-bayer-to-continue-developing-biological-products-for-agriculture-focusing-on-microbial-nitrogen-fixation

Ginkgo Bioworks (NYSE:DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to adv...

 ginkgo-bioworks-collaborates-with-strmbio-and-university-of-british-columbia-to-develop-in-vivo-chimeric-antigen-receptor-therapies-for-autoimmune-diseases

Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo C...

 btig-maintains-sell-on-ginkgo-bioworks-holdings-raises-price-target-to-9

BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and raises the price target from $6 to $9.

 5-healthcare-stocks-on-fire-this-week

Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech &...

 ginkgo-bioworks-announces-strategic-partnership-to-scale-ai-drug-discovery-via-datapoints-platform

Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that i...

 ginkgo-bioworks-holdings-q2-eps-110-beats-156-estimate-sales-5000m-beat-4161m-estimate

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of...

 ginkgo-bioworks-holdings-affirms-fy2025-sales-guidance-of-167000m-187000m-vs-178213m-est

Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 million to $167.000 million-$18...

 ginkgo-bioworks-to-build-automated-anaerobic-phenotyping-platform-for-emsl-using-reconfigurable-automation-cart-technology

Ginkgo will build a platform driven by its Reconfigurable Automation Carts (RACs) technology to enable EMSL's open-ended ex...

Core News & Articles

New terms provide Twist with key license to long DNA technology and assetsGinkgo to continue ordering from Twist with no purcha...

 ginkgo-bioworks-holdings-updates-fy2025-sales-guidance-from-16000m-18000m-to-16700m-18700m-vs-20201m-est

Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; a...

 nvidia-backed-recursion-ginkgo-bioworks-rally-following-fdas-decision-to-end-animal-testing

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION